Silexion Therapeutics regains Nasdaq compliance; subject to one-year monitor

Silexion Therapeutics Corp

Received Nasdaq compliance letter on Sep 23, 2025 for equity (≥$2.5M) and minimum bid price ($1.00) requirements.
Financing transactions increased shareholders' equity by $10.3M to ~$9.41M as of Sep 15, 2025.
1-for-15 reverse stock split on Jul 29, 2025 brought bid price above $1.00.
Subject to mandatory panel monitor until Sep 23, 2026; any future non-compliance may lead to immediate delisting.

item 8.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.